| Filed On | Filing |
|---|---|
| 12 Nov 2026 | 10-Q/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
OraSure Announces Third Quarter 2026 Financial Results; Strategic Execution Drives Double-Digit Year-Over-Year Growth and Margin Expansion |
| 09 Nov 2026 | SCHEDULE 13G/A |
| 30 Oct 2026 | SCHEDULE 13G/A |
| 01 Oct 2026 |
Form 4: Boyd Steven Kyle, Director
Received 4,797 shares as a grant or award ($18.6K) |
| 17 Sep 2026 | SCHEDULE 13D |
| 09 Sep 2026 |
Form 4: Kenny John P., Director
Gave up 5,116 shares to cover exercise price or tax ($17.5K) |
| 12 Aug 2026 | SCHEDULE 13G |
| 07 Aug 2026 | S-8 |
| 07 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months e... |
| 31 Jul 2026 | SCHEDULE 13G/A |
| 30 Jun 2026 |
Form 4: Boyd Steven Kyle, Director
Received 3,666 shares as a grant or award ($16.2K) |
| 11 Jun 2026 |
8-K: Other Events
On June 11, 2026, OraSure Technologies, Inc. (the “Company”) announced U.S. Food and Drug Administration (“FDA”) clearance of the Company’s Colli-Pee™•Dx Urine Collection Kit from its subsidiary DNA Genotek Inc., for use with Roche Molec... |
| 05 Jun 2026 |
Form 4: McMahon Robert W., Director
Received 46,106 shares as a grant or award |
| 05 Jun 2026 |
Form 4: Gagliano Nancy J, Director
Received 46,106 shares as a grant or award |
| 05 Jun 2026 |
Form 4: Marmora Lelio, Director
Received 46,106 shares as a grant or award |
| 05 Jun 2026 |
Form 4: Kenny John P., Director
Received 46,106 shares as a grant or award |
| 05 Jun 2026 |
Form 4: Bertrand John D., Director
Received 46,106 shares as a grant or award |
Loading...